Perspective Therapeutics (NYSE: CATX) insider transactions
In the twelve months to 10 November 2026, executives and directors of Perspective Therapeutics reported 7 open-market sales of 517,889 shares ($1.6m) and 2 open-market purchases of 20,498 shares ($42,276), by 4 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 4 September 2026 | Lantheus Alpha Therapy, LLC | — | Open-market sale | −167,149 | $3.15 | 11,273,364 | Form 4 |
| 3 September 2026 | Lantheus Alpha Therapy, LLC | — | Open-market sale | −80,783 | $3.11 | 11,440,513 | Form 4 |
| 2 September 2026 | Lantheus Holdings, Inc. | — | Open-market sale | −42,129 | $3.11 | 11,521,296 | Form 4 |
| 1 September 2026 | Lantheus Alpha Therapy, LLC | — | Open-market sale | −35,769 | $3.12 | 11,563,425 | Form 4 |
| 1 September 2026 | Lantheus Holdings, Inc. | — | Open-market sale | −35,769 | $3.12 | 11,563,425 | Form 4 |
| 31 August 2026 | Lantheus Alpha Therapy, LLC | — | Open-market sale | −78,145 | $3.14 | 11,599,194 | Form 4 |
| 31 August 2026 | Lantheus Holdings, Inc. | — | Open-market sale | −78,145 | $3.14 | 11,599,194 | Form 4 |
| 13 November 2025 | Hunt Jonathan Robert | Chief Accounting Officer | Open-market purchase | +11,000 | $2.03 | 59,800 | Form 4 |
| 12 November 2025 | Williamson Robert F III | Director | Open-market purchase | +9,498 | $2.10 | 9,864 | Form 4 |
| 31 March 2025 | Woods Lori A | Director | Open-market purchase | +23,475 | $2.13 | 183,460 | Form 4 |
| 31 March 2025 | Williamson Robert F III | Director | Open-market purchase | +38,145 | $2.14 | 108,982 | Form 4 |
| 28 March 2025 | Graham Juan | Chief Financial Officer | Open-market purchase | +33,333 | $2.25 | 35,354 | Form 4 |
| 28 March 2025 | Williamson Robert F III | Director | Open-market purchase | +22,192 | $2.27 | 70,837 | Form 4 |
| 28 March 2025 | Spoor Johan M. | Chief Executive Officer | Open-market purchase | +22,026 | $2.24 | 59,383 | Form 4 |
| 28 March 2025 | Spoor Johan M. | Chief Executive Officer | Open-market purchase | +4,650 | $2.21 | 4,650 | Form 4 |
| 4 December 2024 | Henson Heidi | Director | Open-market purchase | +25,975 | $3.85 | 25,975 | Form 4 |
| 4 December 2024 | Spoor Johan M. | CEO | Open-market purchase | +8,000 | $3.77 | 36,257 | Form 4 |
| 25 November 2024 | Hunt Jonathan Robert | Chief Financial Officer | Open-market purchase | +400 | $3.55 | 36,371 | Form 4 |
| 25 November 2024 | Hunt Jonathan Robert | Chief Financial Officer | Open-market purchase | +29 | $3.94 | 36,400 | Form 4 |
| 25 November 2024 | Hunt Jonathan Robert | Chief Financial Officer | Open-market purchase | +2,400 | $3.60 | 38,800 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Perspective Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.